Learned metabolite selection supports a thrombosis classification panel in coronary-heart-disease patients
Source check: Source checked. Not independent scientific confirmation.
Finding: LASSO and random-forest selection identified a six-metabolite panel associated with Doppler-defined post-traumatic deep-vein thrombosis among patients with coronary heart disease. The source reports evaluation of the resulting classifier in a separate same-center clinical cohort. These are retrospective biomarker associations and diagnostic discrimination; the study does not establish that the metabolites cause thrombosis or that predicted drug candidates are effective.
Technology: LASSO regression and random-forest feature selection; logistic classification
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Learned sparse regression and RF feature ranking selected the six-metabolite subset from measured profiles, enabling construction and separate-cohort evaluation of the represented clinical classification panel.
- Test and result
- The source describes 218 discovery participants, comprising 93 thrombosis-plus-coronary-disease cases and 125 coronary-disease controls, and a separate 86-person validation cohort with 39 cases and 47 controls. A 2000-tree RF and LASSO selected six overlapping metabolite features, used in logistic diagnostic models. The original Methods describe clinical Doppler reference assessment, model construction and evaluation in the separate cohort.
- Limitation / still unknown
- Both cohorts came from one hospital and underwent different analytical batches. Differential screening preceded internal train/test modeling; some preprocessing used dataset-wide information, so internal split results are not a wholly untouched pipeline evaluation. The paper describes different internal split ratios for feature-selection and final-model stages. Blood sampling and Doppler confirmation were not simultaneous in every patient, and causal pathway interpretation is not established. Metabolite/protein totals vary across source sections; those totals and simulated therapeutic candidates are not represented as verified findings.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1007/s11306-026-02419-3
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Read actual clinical recruitment/reference timing, discovery/validation groups, preprocessing/feature-selection/model Methods, six-feature intersection and diagnostic-model Results. Causal sphingolipid and drug-screen claims are excluded from the represented finding. Original canonical online March 28 distinguished from April issue. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.